Background: Curcumin is seen as an anti-hyperglycemic agent that acts by improving the expression of glucose transporters. It is also related to the reduction of glycosylated hemoglobin, improvement of insulin sensitivity, plasma lipids, and blood pressure. Aim: The purpose of this article is to review the effects of Curcuma longa in insulin resistance. Methodology: PUBMED and EMBASE databases were searched, and PRISMA (Preferred Reporting Items for a Systematic Review and Meta-analysis) guidelines were followed to build the review. Results: Nineteen Randomized Clinical Trials (RCTs) met the inclusion criteria and were described according to PICO (Population, Intervention, Comparison, and Outcomes). Conclusion: Curcumin could be considered in the therapeutic approach of patients with Insulin Resistance, once it is related to the reduction of oxidative stress, inflammation, serum fasting blood glucose, HOMA-IR, blood pressure, serum lipids, and liver transaminases. However, the results depend on the dose, intervention time, and formulation of the compound.Insulin resistance